Nature Reviews Drug Discovery

Article	Citations
The importance of persistence in cancer drug development	1888
A new path to targeted protein degradation?	1791
A specific biomarker for insoluble tau	1139
Targeting tumour-associated bacteria	1093
The improving benefit–risk balance of phase I cancer trials	969
Neutralizing Zika virus	743
Upcoming market catalysts in Q3 2021	651
Vaccine exposes tumours to immune cell attack	556
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	549
Promoting tissue repair after heart attack	490
mRNA-encoded monoclonal antibody fights CHIKV	488
AI serves up target and inhibitor for lung fibrosis	484
FDA approves first all-oral sleeping sickness drug	408
Hypoimmune iPSCs escape immune detection	404
Glucose-sensitive insulin protects against hypoglycaemia	402
Tumour cells get a dendritic cell makeover	402
Degrading cell-free DNA to prevent recurrent stroke	372
Apolipoprotein L2 inhibitor mitigates fibrosis	368
FDA new drug approvals in Q1 2023	368
Lipid nanoparticle ferries therapeutic mRNA to the placenta	365
FDA approves second TTR stabilizer for cardiac amyloidosis	362
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	356
Targeting drug-resistant glioblastoma	345
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	337
New antibiotic for urinary tract infections nabs FDA approval	317

Chemical engineering of CRISPR–Cas systems for therapeutic application	279
2022 FDA approvals	273
Anti-tau antibody stumbles in phase II Alzheimer trial	254
Evolution of innovative drug R&D in China	252
Top companies and drugs by sales in 2021	249
Small-molecule discovery through DNA-encoded libraries	245
mRNA vaccines for infectious diseases — advances, challenges and opportunities	242
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	238
Increasing the potency of T cell therapies	222
Pushing both sides of the drug pricing aisle	218
Predicting Alzheimer disease dementia	207
Reflections on 10 years of the FDA’s breakthrough therapy designation	204
Blocking breast cancer metastasis	194
Rewired proteostasis in KRAS inhibitor resistance	192
Small molecule improves muscle function in myasthenia gravis	189
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	182
R&D re-balancing act	181
Host-directed antiviral blocks SARS-CoV-2 entry	177
Author Correction: mRNA vaccines for infectious diseases: principles, delivery and clinical translation	159
The significance of blockbusters in the pharmaceutical industry	157
TCR-engineered T cells get personal	156
Screening ultra-large virtual libraries	156
A call to action for translational sciences in COVID-19 and future pandemics	155
FDA new drug approvals in Q2 2023	153
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	151
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	146
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	145
Base editors hit the clinic	143
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	143
The antibody–drug conjugate landscape	142
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	138
FDA approves second BCMA-targeted CAR-T cell therapy	136
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	131
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	130
Amylin takes another shot at the obesity prize	117
Pan-coronavirus vaccine pipeline takes form	113
Combating antimicrobial resistance in malaria, HIV and tuberculosis	112
Inhibiting ASGR1 boosts cholesterol removal	111
Phenotypic drug discovery: recent successes, lessons learned and new directions	108
Antibody–drug conjugates come of age in oncology	107
The emerging role of mass spectrometry-based proteomics in drug discovery	107
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials	105
Gut metabolite mediates nerve repair	101
Agonist antibody lowers blood pressure	100
Reducing IL-2 toxicity	100
A novel single-agent antibiotic	99
Immunology on the brain	99
Multi-TACs target solid tumours	94
The malignant melanoma market	92
What does AlphaFold mean for drug discovery?	90

Neglected tropical diseases go global	85
Monkeypox mRNA vaccine protects mice and macaques	85
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	85
Anti-IL-11 antibody shows anti-ageing properties	84
The European Innovation Network as a hub for medicines innovation in Europe	84
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	81
Author Correction: PI3K inhibitors are finally coming of age	80
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	79
Ribosome inhibitor combats bacterial drug resistance	76
LRRK2-targeted Parkinson disease drug advances into phase III	75
Frameworks for transformational breakthroughs in RNA-based medicines	73
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	72
Engineered parasite delivers proteins to the brain	72
Avidity in antibody effector functions and biotherapeutic drug design	72
Engineering a compact genome-editing tool	71
Upcoming market catalysts in Q4 2023	70
Docking downstream to treat myasthenia	70
RNA structure guides antiviral ASO design	69
Delivering genome editing tools to primary cells	68
Giving antibiotics a boost	66
Covalent inhibitor engages oncogenic AKT kinase	66
Publisher Correction: Roflumilast	65
FDA approves first PSMA-targeted radiopharmaceutical	65
A rush of CRISPR to the lungs	63
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor	63
Accelerating precision oncology by converging pragmatic trials and real-world evidence	61
MYC in cancer: from undruggable target to clinical trials	61
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems	60
The PROTACtable genome	59
AAV-based in vivo gene therapy for neurological disorders	59
Investigating the origins of recent pharmaceutical innovation	59
Promoting efferocytosis heals diabetic wounds	56
Identification of neoantigens for individualized therapeutic cancer vaccines	55
V-ATPase inhibitor targets Ras-mutant cancers	52
A bacteria-derived oral tumour vaccine	51
Three-step cures for autoimmune diseases?	49
Immuno-oncology target TIGIT attracts a new contender	48
RNA delivery heats up cold tumours	47
Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases	42
Designing novel macrocyclic drugs	42
Microbial ‘dark matter’ yields new antibiotic	41
Upcoming market catalysts in Q4 2024	40
Analysis of China-to-West pharmaceutical licensing deals in 2024	38
The case for cell-penetrating peptides	38
Can large, simple trials bring drug developers back to common diseases?	38
2023 FDA approvals: unprecedented volume at moderate value	38
The market for ulcerative colitis	37
Understanding LAG3 immune checkpoint function	36
Glue-based KRAS inhibitors make their debut cancer trial mark	36
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy	35
PPAR agonists provide new treatment options for inflammatory liver disease	35
Hinge modifier approach opens door to drugging HECT E3 ligases	34
FDA approves cell-sheet-based gene therapy for severe skin disease	33
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics	32
Cartilage regeneration for osteoarthritis	32
Novel strategies to manage CAR-T cell toxicity	32
Therapeutically harnessing extracellular vesicles	31
A new drug target for NRAS(Q61) mutant-expressing cancers	31
eEF2K: an atypical kinase target for cancer	30
Synthetic cytokine circuit targets solid tumours	29
The 60-year evolution of lipid nanoparticles for nucleic acid delivery	29
Refining HIV pre-exposure prophylactic agents	28
Designing closure-stabilizing integrin inhibitors	28
miR-21 antagomir reverses COPD pathology	28
Targeting sigma receptor 1 in long QT syndrome	28
Transcription reprogramming to enhance CAR-T cell function	27
A faster route to antidepressant activity	26
FDA approves PI3Kα inhibitor that does double duty as a degrader	26
Publisher Correction: Evolution of the market for mRNA technology	26
Novel schizophrenia therapy filed for FDA approval	25
Designing a novel synthetic receptor	25
FDA approves 21-valent pneumococcal vaccine	24
Anti-histamines boost immunotherapy	24
A step closer to in vivo editing of haematopoietic stem cells	24
Genome-editing medicinal products: the EMA perspective	23
Improving efficacy of ASO therapy in SMA	23
CAR T cells take to the airways	23
FDA approves decades-old maribavir for CMV infection	23
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments	22
Sequential immunotherapy: towards cures for autoimmunity	21

Top product forecasts for 2025	21
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation	21
Drugging the efferocytosis process: concepts and opportunities	20
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	20
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)	19
In vivo CAR T cells move into clinical trials	19
RNAi-based drug design: considerations and future directions	19
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	19
Targeting galectin-driven regulatory circuits in cancer and fibrosis	18
Acyl-lysine reader inhibitor blocks AML progression	18
Bacteria tag tumours for CAR-T cell attack	18
Putting a PIN in pancreatic cancer	18
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform	18
Understanding the effects of antibiotic combinations	18
Synthesizing portimines	18
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion	17
Rediscovering hygromycin A for Lyme disease treatment	16
Open-science drug discovery for COVID-19	16
Treating cannabis use disorder	16
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics	16
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	15
Epigenetic editor silences prion protein	15
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	15
Brain glucose mediates amphotericin B tolerance	15
Stalled molecular motor inhibits tumour growth	15
ASO targets DNA repair protein to combat Huntington disease	15
Neurons give metastatic cells a push	15
Trends in the drug target landscape for autoimmune diseases	14
Insights into new approach methodology innovation: an EMA perspective	14
opnMe.com: a digital initiative for sharing tools with the biomedical research community	14
The KRAS crowd targets its next cancer mutations	14
Antibody cocktail eliminates ebolaviruses	13
Trustworthy AI for safe medicines	13
mRNA flu shots move into trials	13
Understanding sphingosine-1-phosphate transport	13
Advanced technologies for the development of infectious disease vaccines	13
Thinking outside the box: non-canonical targets in multiple sclerosis	13
Targeting ALDH1B1 in colorectal cancer	13
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	13
Bispecific antibodies in oncology	13
A new antibiotic for A. baumannii	13
A type 1 regulatory T cell-based therapy	12
Phosphatase inhibitor drives anticancer immune responses	12
Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennial	12
Alnylam scores big pharma support for angiotensinogen silencer	12
FDA releases tissue-agnostic cancer drug draft guidance	12
Understanding immunomodulatory antibody agonism	12
Upcoming market catalysts in Q3 2023	12
Gene editing addresses antithrombin deficiency	12
Nonhormonal target for endometriosis	12
Setting GPCRs free	11
T cell-regulating therapies for autoimmune diseases take FDA rejection in stride	11
FDA approves first claudin-18.2-targeted antibody for gastric cancer	11
FDA approves first two drugs for rare Niemann–Pick disease	11
Top product forecasts for 2022	11
Sensitizing glioblastoma to radiotherapy	11
DUBTACs for targeted protein stabilization	11
The renal cell carcinoma drug market	11
Ramping up mitochondrial DNA replication	10
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications	10
Macrophages as tools and targets in cancer therapy	10
FDA approves first chikungunya vaccine	10
Hooking FSH as a potential target for Alzheimer disease	10
Targeting expanded trinucleotide repeats	10
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	10
Reactivating PTEN promotes antitumour immunity	10
Targeting cytokine networks in neuroinflammatory diseases	10
Membrane transporters in drug development and as determinants of precision medicine	10
FDA approves second anti-amyloid antibody for Alzheimer disease	9
Chromatin-targeted drug discovery at “a very special moment”	9
Targeting ephrin signalling in sepsis	9
Inhibiting metallo-β-lactamases	9
mRNA vaccine for Lyme disease prevention	9
Novel drug targets in 2021	9
FDA approves PI3K inhibitor for a rare immune disorder	9
Two-pronged approach for macular degeneration	9
New therapeutic candidate for Chagas disease	8
BacPROTAC to treat tuberculosis	8
New route to target RAS	8
Novel drug targets in 2023	8
Scooping up all the drugs	8
Antibody drug conjugate combats inflammation	8
Mapping cysteine ligandability	8
Repurposing beta-blockers in breast cancer	8
2022 FDA approval number dips: a COVID-19 hangover?	8
Hitting SEND on mRNA delivery	8
Opportunities for mitochondrial disease gene therapy	7
Immune targets for therapeutic development in depression: towards precision medicine	7
Targeting immunogenic cell stress and death for cancer therapy	7
The potential of innovative trial design for efficiently evaluating repurposed drugs	7
Deuterium in drug discovery: progress, opportunities and challenges	7
2023 FDA approvals	7
ALS antisense drug falters in phase III	7
BCMA-targeted bispecific gets first green light, in the EU	7
RNF41 reverses liver fibrosis	7